• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

应用 MAPP 分析评估药物免疫原性。

Applying MAPPs Assays to Assess Drug Immunogenicity.

机构信息

Novartis Institute for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.

出版信息

Front Immunol. 2020 Apr 21;11:698. doi: 10.3389/fimmu.2020.00698. eCollection 2020.

DOI:10.3389/fimmu.2020.00698
PMID:32373128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7186346/
Abstract

Immunogenicity against biotherapeutic proteins (BPs) and the potential outcome for the patient are difficult to predict. assays that can help to assess the immunogenic potential of BPs are not yet used routinely during drug development. MAPPs (MHC-associated peptide proteomics) is one of the assays best characterized regarding its value for immunogenicity potential assessment. This review is focusing on recent studies that have employed human HLA class II-MAPPs assays to rank biotherapeutic candidates, investigate clinical immunogenicity, and understand mechanistic root causes of immunogenicity. Advantages and challenges of the technology are discussed as well as the different areas of application.

摘要

针对生物治疗性蛋白 (BP) 的免疫原性及其对患者的潜在影响很难预测。在药物开发过程中，目前还没有常规使用有助于评估 BP 免疫原性潜力的检测方法。MAPPs（MHC 相关肽蛋白质组学）是评估免疫原性潜力方面特征描述最好的检测方法之一。本综述重点关注最近使用人类 HLA Ⅱ类-MAPPs 检测方法对生物治疗候选药物进行分级、研究临床免疫原性以及了解免疫原性机制根本原因的研究。还讨论了该技术的优缺点以及不同的应用领域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/86cfc5fc2ec9/fimmu-11-00698-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/313661cf1d3f/fimmu-11-00698-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/70ea28b56c00/fimmu-11-00698-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/ab7cd867dbd0/fimmu-11-00698-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/86cfc5fc2ec9/fimmu-11-00698-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/313661cf1d3f/fimmu-11-00698-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/70ea28b56c00/fimmu-11-00698-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/ab7cd867dbd0/fimmu-11-00698-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a976/7186346/86cfc5fc2ec9/fimmu-11-00698-g0004.jpg

相似文献

1
Applying MAPPs Assays to Assess Drug Immunogenicity.应用 MAPP 分析评估药物免疫原性。
Front Immunol. 2020 Apr 21;11:698. doi: 10.3389/fimmu.2020.00698. eCollection 2020.
2
Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development.开发一种基于链霉亲和素珠的免疫亲和捕获和纳升液相色谱-串联质谱的半自动化 MHC 相关肽蛋白质组学 (MAPPs) 方法，以支持药物开发中的免疫原性风险评估。
Front Immunol. 2023 Nov 10;14:1295285. doi: 10.3389/fimmu.2023.1295285. eCollection 2023.
3
MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity.MHC 相关肽蛋白质组学可实现对免疫原性序列的高灵敏度检测，从而开发低免疫原性的治疗性抗体。
MAbs. 2018 Nov-Dec;10(8):1168-1181. doi: 10.1080/19420862.2018.1518888. Epub 2018 Oct 1.
4
Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.司库奇尤单抗是一种新型抗白细胞介素-17A抗体，在人体体外试验中显示出较低的免疫原性潜力，与其他具有低临床免疫原性的已上市生物疗法相当。
MAbs. 2016;8(3):536-50. doi: 10.1080/19420862.2015.1136761. Epub 2016 Jan 28.
5
MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena.用于鉴定生物治疗药物免疫原性热点的 MAPPs；技术概述及其在生物制药领域的应用。
Expert Rev Proteomics. 2018 Sep;15(9):733-748. doi: 10.1080/14789450.2018.1521279. Epub 2018 Sep 17.
6
Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins.提高 HLA 抗原呈递热点预测：在治疗性蛋白免疫原性风险评估中的应用。
Immunology. 2021 Feb;162(2):208-219. doi: 10.1111/imm.13274. Epub 2020 Oct 19.
7
Specificity of the T Cell Response to Protein Biopharmaceuticals.蛋白类生物制药的 T 细胞反应的特异性。
Front Immunol. 2020 Jul 22;11:1550. doi: 10.3389/fimmu.2020.01550. eCollection 2020.
8
Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction.免疫肽组学数据集成到人工神经网络中可提高蛋白质药物免疫原性预测。
Front Immunol. 2020 Jun 23;11:1304. doi: 10.3389/fimmu.2020.01304. eCollection 2020.
9
Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity.治疗性抗体被内吞进入树突状细胞是其产生免疫原性的一个风险因素。
Front Immunol. 2024 Aug 28;15:1406643. doi: 10.3389/fimmu.2024.1406643. eCollection 2024.
10
Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics.评估 MAPPs 分析作为预测蛋白质治疗药物免疫原性潜力的工具。
Life Sci Alliance. 2023 Oct 13;7(1). doi: 10.26508/lsa.202302095. Print 2024 Jan.

引用本文的文献

1
Epitope mapping using immunopeptidomics reveals novel immunodominant CD8 T cell epitopes of the AAV9 capsid.使用免疫肽组学进行表位作图揭示了AAV9衣壳新的免疫显性CD8 T细胞表位。
Front Immunol. 2025 Aug 8;16:1641289. doi: 10.3389/fimmu.2025.1641289. eCollection 2025.
2
Immunogenicity Risk Assessment of Biotherapeutics Using an Ex Vivo B Cell Assay.使用体外B细胞检测法对生物治疗药物进行免疫原性风险评估。
Antibodies (Basel). 2025 Jul 22;14(3):62. doi: 10.3390/antib14030062.
3
PepMapViz: a versatile toolkit for peptide mapping, visualization, and comparative exploration.

本文引用的文献

1
T cell epitope mapping of secukinumab and ixekizumab in healthy donors.在健康供体中对司库奇尤单抗和依奇珠单抗的 T 细胞表位进行定位。
MAbs. 2020 Jan-Dec;12(1):1707418. doi: 10.1080/19420862.2019.1707418.
2
Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes.治疗性抗体可变区中的人类序列对CD4 T细胞表位定位的影响。
Cell Mol Immunol. 2020 Jun;17(6):656-658. doi: 10.1038/s41423-019-0304-3. Epub 2019 Oct 28.
3
A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.
PepMapViz：用于肽图谱分析、可视化及比较探索的多功能工具包。
Bioinformatics. 2025 Jul 1;41(7). doi: 10.1093/bioinformatics/btaf404.
4
Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment.超越疗效：通过免疫原性评估确保肽类疗法的安全性。
J Pept Sci. 2025 Jun;31(6):e70016. doi: 10.1002/psc.70016.
5
Evaluating the Immunogenicity Risk of Protein Therapeutics by Augmenting T Cell Epitope Prediction with Clinical Factors.通过结合临床因素增强T细胞表位预测来评估蛋白质治疗药物的免疫原性风险
AAPS J. 2025 Jan 23;27(1):33. doi: 10.1208/s12248-024-01003-8.
6
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation.通过糖基化调节可溶性血管紧张素转换酶2诱饵受体的药代动力学。
Mol Ther Methods Clin Dev. 2024 Jul 19;32(3):101301. doi: 10.1016/j.omtm.2024.101301. eCollection 2024 Sep 12.
7
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies.用于治疗性抗体免疫原性风险评估和人源同源性筛选的计算方法。
MAbs. 2024 Jan-Dec;16(1):2333729. doi: 10.1080/19420862.2024.2333729. Epub 2024 Mar 27.
8
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics.T 细胞和 B 细胞表位分析用于抗体类药物的免疫原性评估和缓解。
MAbs. 2024 Jan-Dec;16(1):2324836. doi: 10.1080/19420862.2024.2324836. Epub 2024 Mar 21.
9
Study on the structure-activity relationship of rice immunopeptides based on molecular docking.基于分子对接的水稻免疫肽构效关系研究
Food Chem X. 2024 Jan 24;21:101158. doi: 10.1016/j.fochx.2024.101158. eCollection 2024 Mar 30.
10
comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira or undergoing repeated switches between Humira and AVT02.比较免疫原性评估（EVCIA），以确定接受修美乐或在修美乐与AVT02之间反复换药的慢性斑块状银屑病患者的相对免疫原性。
Immunother Adv. 2023 Dec 21;4(1):ltad029. doi: 10.1093/immadv/ltad029. eCollection 2024.
单一 T 细胞表位驱动多发性硬化症患者对那他珠单抗的中和性抗药物抗体反应。
Nat Med. 2019 Sep;25(9):1402-1407. doi: 10.1038/s41591-019-0568-2. Epub 2019 Sep 9.
4
Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.在单核细胞衍生的树突状细胞上鉴定的肽：FVIII 产品临床免疫原性的标志物。
Blood Adv. 2019 May 14;3(9):1429-1440. doi: 10.1182/bloodadvances.2018030452.
5
Enhanced Prediction of Hot Spots at Protein-Protein Interfaces Using Extreme Gradient Boosting.利用极端梯度提升增强蛋白质-蛋白质界面热点预测。
Sci Rep. 2018 Sep 24;8(1):14285. doi: 10.1038/s41598-018-32511-1.
6
MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity.MHC 相关肽蛋白质组学可实现对免疫原性序列的高灵敏度检测，从而开发低免疫原性的治疗性抗体。
MAbs. 2018 Nov-Dec;10(8):1168-1181. doi: 10.1080/19420862.2018.1518888. Epub 2018 Oct 1.
7
MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena.用于鉴定生物治疗药物免疫原性热点的 MAPPs；技术概述及其在生物制药领域的应用。
Expert Rev Proteomics. 2018 Sep;15(9):733-748. doi: 10.1080/14789450.2018.1521279. Epub 2018 Sep 17.
8
In Immunopeptidomics We Need a Sniper Instead of a Shotgun.在免疫肽组学中，我们需要的是狙击手，而不是猎枪。
Proteomics. 2018 Jun;18(12):e1700464. doi: 10.1002/pmic.201700464. Epub 2018 Mar 7.
9
Membranal and Blood-Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition.采用数据依赖和独立采集方法分析膜结合和血液可溶性 HLA Ⅱ类肽组。
Proteomics. 2018 Jun;18(12):e1700246. doi: 10.1002/pmic.201700246. Epub 2018 Mar 14.
10
Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?调节肽与抗原呈递受损：IVIg 免疫调节作用的驱动因素？
Immun Inflamm Dis. 2017 Dec;5(4):400-415. doi: 10.1002/iid3.167. Epub 2017 May 31.